Streetbeat News

Legal

AAPL

AMZN

GOOGL

META

MSFT

NVDA

The U.S. Justice Department and the Federal Trade Commission have finalized an agreement to investigate potential antitrust issues involving Microsoft, Nvidia, and OpenAI in the AI sector. This move highlights increased regulatory scrutiny on AI industry concentration. Nvidia and Microsoft are under specific investigation for their market dominance and partnerships.

Portfolio Pulse from Shivani Kumaresan

June 07, 2024 | 11:51 am

F

VWAGY

Republican lawmakers have called for a ban on Chinese battery suppliers CATL and Gotion High-Tech, which are connected to Ford and Volkswagen, over forced labor allegations. They have urged the Biden administration to add these companies to the import ban list under the Uyghur Forced Labor Prevention Act. This comes amid new tariffs on Chinese EV batteries and other products.

Portfolio Pulse from Anan Ashraf

June 07, 2024 | 10:03 am

BTCUSD

SQ

Jack Dorsey's $10 million donation to the decentralized social-media protocol Nostr has inadvertently funded a developer with ties to a Brazilian fascist. The developer, Giovanni Torres Parra, has created webpages supporting far-right conspiracy theorist Olavo de Carvalho. Despite the controversy, Dorsey remains a vocal advocate for Nostr.

Portfolio Pulse from Benzinga Neuro

June 07, 2024 | 6:48 am

BNBUSD

Former federal agents and prosecutors are urging U.S. Secretary of State Antony Blinken to take action for the release of Tigran Gambaryan, Binance's head of compliance, who is detained in Nigeria. This comes amid escalating tensions between Binance and the Nigerian government, which has imposed a $10 billion penalty on the company.

Portfolio Pulse from Aniket Verma

June 07, 2024 | 6:17 am

NFLX

Netflix Inc. (NASDAQ:NFLX) is facing a $170 million defamation lawsuit filed by Fiona Harvey, who claims she was falsely depicted as a stalker in the mini-series 'Baby Reindeer.' Harvey alleges that the portrayal has caused her significant harm and is seeking substantial damages. Netflix intends to defend the lawsuit vigorously.

Portfolio Pulse from Shivdeep Dhaliwal

June 07, 2024 | 2:44 am

DWAC

Trump Media & Technology has sent a fourth letter to the Chairmen of several U.S. House Committees to follow up on previous letters concerning potential stock manipulation.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 9:33 pm

AAPL

A new report by cllct reveals that some sealed iPhones sold at auctions may have been resealed, raising concerns about their authenticity. This could impact the market for these collectibles, potentially making authentic sealed iPhones more scarce and volatile in price.

Portfolio Pulse from Chris Katje

June 06, 2024 | 9:11 pm

MO

The FDA has rescinded the marketing denial orders (MDOs) issued to JUUL Labs Inc., returning the applications to pending status. This decision follows new case law and additional information provided by JUUL. The FDA continues its review of JUUL's applications, which must be authorized to be legally marketed. The rescission comes after the FDA's updated understanding of e-cigarette products and recent litigation outcomes. JUUL, which owns 41% of the $21.63 billion e-cigarette market, had faced a potential ban and financial difficulties.

Portfolio Pulse from Vandana Singh

June 06, 2024 | 6:08 pm

GL

Globe Life Inc (NYSE:GL) shares fell by 2.5% to $81.44 after The Bear Cave issued a report accusing the company of issuing unwanted policies, losing track of active policies, and improperly delaying or denying payouts. The report also alleges deceptive marketing practices and false claims of affiliation with the Department of Veteran Affairs. Globe Life's quarterly dividend is $0.24 per share, with a yield of 1.24%.

Portfolio Pulse from Henry Khederian

June 06, 2024 | 5:24 pm

NVS

RHHBY

Italy's antitrust regulator is investigating Novartis AG and Roche Holdings AG-controlled Genentech for allegedly restricting competition in the sale of an eye drug, Byooviz. The probe focuses on potential delays in the Italian market launch of Byooviz, a biosimilar of Lucentis, due to coordinated strategies by these companies. The investigation could impact drug availability and prices for patients.

Portfolio Pulse from Vandana Singh

June 06, 2024 | 5:19 pm